Lotus, a publicly listed pharmaceutical company on the Taiwan Stock Exchange will expand its R&D capabilities with a new centre in Hyderabad. The company has established a subsidiary, Meishi Pharma Services, with a Rs 36-crore investment.

The proposed centre, as a 20,000 sq. ft. facility to be located in Genome Valley will house around 100 employees and be developed in two phases: Phase-1 operational by Q2 2025 and Phase-2 by Q4 2025. The centre will focus on pharmaceutical formulation development, analytical research, intellectual property management, and clinical project management, as well as other allied research functions

Meishi Pharma Services aims to collaborate with local institutions and industry leaders to foster innovation. The company is committed to investing in advanced technologies and nurturing a skilled workforce, reinforcing Hyderabad’s status as a life sciences hub. As part of its strategic vision, Meishi Pharma Services aims to collaborate with local institutions and industry leaders to drive innovation and contribute to the growth of the life sciences sector in Hyderabad.